Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects

Bioconjugate Chemistry

Volumn 21, Issue 5, 2010, Pages 797-802

  Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTINEOPLASTIC AGENT; GLYCERYL TRINITRATE; KININ; NITRIC OXIDE; PROSTAGLANDIN; PROTEINASE;

BACTERIAL INFECTION; BLOOD FLOW; BLOOD PRESSURE; CANCER THERAPY; CANCER TISSUE; CELL HETEROGENEITY; DRUG DELIVERY SYSTEM; ENHANCED PERMEABILITY AND RETENTION EFFECT; HEART INFARCTION; HUMAN; MACROMOLECULE; NEOPLASM; REVIEW; SURFACE PROPERTY; THERAPY EFFECT;

BACTERIA (MICROORGANISMS); RODENTIA;

EID: 77952575335     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100070g     Document Type: Review

References (47)

1. Maeda, H., Edo, K., and Ishida, N., Eds. (1997) Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug, pp 1 - 289, Springer-Verlag, Tokyo.
2. Maeda, H. and Konno, T. (1997) Metamorphosis of neocarzinostatin to SMANCS-chemistry, pharmacology and clinical effect of the first prototype anticancer polymer therapeutic. In Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug (Maeda, H., Edo, K., and Ishida, N., Eds.) pp 227 - 267, Springer-Verlag, Tokyo.
3. Maeda, H., Ueda, M., Morinaga, T., and Matsumoto, T. (1985) Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: Pronounced improvements in pharmacological properties J. Med. Chem. 28, 455-461
4. Kobayashi, A., Oda, T., and, and Maeda, H. (1988) Protein binding of macromolecular anticancer agent SMANCS: Characterization of poly(styrene-co- maleic acid) derivatives as an albumin binding ligand J. Bioact. Compat. Polym. 3, 319-333
5. Matsumoto, K., Yamamoto, T., Kamata, R., and Maeda, H. (1984) Pathogenesis of serratial infection: Activation of the Hageman factor-prekallikrein cascade by serratial protease J. Biochem. 96, 739-749
6. Molla, A., Yamamoto, T., Akaike, T., Miyoshi, S., and Maeda, H. (1989) Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases J. Biol. Chem. 264, 10589-10594
7. Maeda, H. (1996) Role of microbial proteases in pathogenesis Microbiol. Immunol. 40, 685-699
8. Maeda, H. (2002) Microbial proteinases and pathogenesis of infection. In Wiley Encyclopedia of Molecular Medicine (Creighton, T. E., Ed.) pp 2663 - 2668, Vol 4, John Wiley & Sons, New York.
9. Maeda, H., Akaike, T., Sakata, Y., and Maruo, K. (1993) Role of bradykinin in microbial infection: Enhancement of septicemia by microbial proteinases and kinin. In Proteases, Proteases Inhibitor and Protease-Derived Peptides: Importance in Human Pathophysiology and Therapeutics. Agents Actions Supplement (Chironis, J. C. and Repine, J. E., Eds.) pp 159 - 165, Vol 42, Birkhauser-Verlag AG, Basel.
10. 3]bradykinin in ascetic fluid from a patient with gastric cancer J. Biol. Chem. 263, 16051-16054
11. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46, 6387-6392
12. Matsumura, Y., Kimura, M., Yamamoto, T., and Maeda, H. (1988) Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue Jpn. J. Cancer Res. 79, 1327-1334
13. Matsumura, Y., Maruo, K., Kimura, M., Yamamoto, T., Konno, T., and Maeda, H. (1991) Kinin-generating cascade in advanced cancer patients and in vitro study Jpn. J. Cancer Res. 82, 732-741
14. Wu, J., Akaike, T., and Maeda, H. (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger Cancer Res. 58, 159-165
15. Maeda, H., Wu, J., Okamoto, T., Maruo, K., and Akaike, T. (1999) Kallikrein-kinin in infection and cancer Immunopharmacology 43, 115-128
16. Maeda, H. (1991) SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy Adv. Drug Delivery Rev. 6, 181-202
17. Iwai, K., Maeda, H., and Konno, T. (1984) Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image Cancer Res. 44, 2115-2121
18. Konno, T., Maeda, H., Iwai, K., Maki, S., Tashiro, S., Uchida, M., and Miyauchi, Y. (1984) Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium Cancer 54, 2367-2374
19. Maki, S., Konno, T., and Maeda, H. (1985) Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium Cancer 56, 751-757
20. Nagamitsu, A., Greish, K., and Maeda, H. (2009) Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: Cases of advanced solid tumors Jpn. J. Clin. Oncol. 39, 756-766
21. Folkman, J. (1974) Tumor angiogenesis Adv. Cancer Res. 19, 331-358
22. Skinner, S. A., Tutton, P. J., and OBrien, P. E. (1990) Microvascular architecture of experimental colon tumors in the rat Cancer Res. 50, 2411-2417
23. Greish, K., Nagamitsu, A., Fang, J., and Maeda, H. (2005) Copoly(styrene-maleic acid)-pirarubicin micelles: High tumor-targeting efficiency with little toxicity Bioconjugate Chem. 16, 230-236
24. Maeda, H., Seymour, L. W., and Miyamoto, Y. (1992) Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo Bioconjugate Chem. 3, 351-362
25. Yokoyama, M., Okano, T., Sakurai, Y., and Kataoka, K. (1994) Improved synthesis of adriamycin-conjugated poly(ethylene oxide)-poly(aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin J. Controlled Release 32, 269-277
26. Duncan, R. (2009) Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt Adv. Drug Delivery Rev. 61, 1131-1148
27. Iyer, A., Greish, K., Seki, T., Okazaki, S., Fang, J., Takeshita, K., and Maeda, H. (2007) Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation J. Drug Targeting 15, 496-506
28. Zalipsky, S., Saad, M., Kiwan, R., Ber, E., Yu, N., and Minko, T. (2007) Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: Insights of the mechanism of action J. Drug Targeting 15, 518-530
29. Fang, J., Nakamura, H., and Iyer, A. K. (2007) Tumor-targeted induction of oxystress for cancer therapy J. Drug Targeting 15, 475-486
30. Kimura, N. T., Taniguchi, S., Aoki, K., and Baba, T. (1980) Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration Cancer Res. 96, 739-749
31. Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z., and Hoffman, R. (2006) Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice Cancer Res. 66, 7647-7652
32. Torchilin, V. (2010) Tumor delivery of macromolecular drugs based on the EPR effect, Adv. Drug Delivery Rev., in press.
33. Maeda, H., Noguchi, Y., Sato, K., and Akaike, T. (1994) Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor Jpn. J. Cancer Res. 85, 331-334
34. Wu, J., Akaike, T., Hayashida, K., Okamoto, T., Okuyama, A., and Maeda, H. (2001) Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinase Jpn. J. Cancer Res. 92, 439-451
35. 2 analogue beraprost sodium J. Drug Targeting 11, 45-52
36. Maeda, H. (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 41, 189-207
37. Suzuki, M., Hori, K., Abe, I., Saito, S., and Saito, H. (1981) A new approach to cancer chemotherapy: A selective enhancement of tumor blood flow with angiotensin II J. Natl. Cancer Inst. 67, 663-669
38. Li, C. J., Miyamoto, Y., Kojima, Y., and Maeda, H. (1993) Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure Br. J. Cancer 67, 975-980
39. Maeda, H., Seki, T., and Fang, J. (2008) Enhanced tumor delivery of macromolecular antitumor-drugs by topical application of nitroglycerin on superficial tumors, Abstract #P-518 in the 67th Annual Meeting of the Japanese Cancer Association, Nagoya, p 213.
40. Seki, T., Fang, J., and Maeda, H. (2009) Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application Cancer Sci. 100, 2426-2430
41. Feelisch, M. and Noack, E. A. (1987) Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase Eur. J. Pharmacol. 139, 19-30
42. Yasuda, H., Yamaya, M., Nakayama, K., Sasaki, T., Ebihara, S., Kanda, A., Asada, M., Inoue, D., Suzuki, T., Okazaki, T., Takahashi, H., Yoshida, M., Kaneta, T., Ishizawa, K., Yamanda, S., Tomita, N., Yamasaki, M., Kikuchi, A., Kubo, H., and Sasaki, H. (2006) Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer J. Clin. Oncol. 24, 688-694
43. Yasuda, H., Nakayama, K., Watanabe, M., Suzuki, S., Fuji, H., Okinaga, S., Kanda, A., Zayasu, K., Sasaki, T., Asada, M., Suzuki, T., Yoshida, M., Yamanda, S., Inoue, D., Kaneta, T., Kondo, T., Takai, Y., Sasaki, H., Yanagihara, K., and Yamaya, M. (2006) Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma Clin. Cancer Res. 12, 6748-6757
44. Siemens, D. R., Heaton, J. P. W., Adams, M. A., Kawakami, J., and Graham, C. H. (2009) Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer Urology 74, 878-883
45. Maeda, H., Bharate, G. Y., and Daruwalla, J. (2009) Polymeric drugs and nanomedicines for efficient tumor targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71, 409-419
46. Daruwalla, J., Greish, K., Wilson, C. M., Muralidharan, V., Iyer, A., Maeda, H., and Christophi, C. (2009) Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases J. Vasc. Res. 46, 218-228
47. Maeda, H., Matsumura, Y., Oda, T., and Sasamoto, K. (1986) Cancer selective macromolecular therapeusis: Tailoring of an antitumor protein drug. In Protein Tailoring for Food and Medical Uses (Feeney, R. E. and Whitaker, J. R., Eds.) pp 353 - 382, Marcel Dekker, Inc., New York.